FGF2 and breast cancer: The investigation into the role of the PI3K/AKT pathway in FGF2-dependent resistance to etoposide, 5-fluorouracil, camptothecin, and the C2 ceramide analogue in breast cancer cell lines (MCF-7, T47-D, and BT-20) revealed subsequent AKT-dependent stimulation and translocation of nuclear factor-κB (NFκB) to the nucleus via activation of IKK-β (inhibitors of NFκB kinase-β), but not on the MAPK pathway [30].